Floatz logo

Adebrelimab

Brain Metastasases

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Brain Metastasases cohort.

Asset / SponsorPhaseRating
jk-1201i
JenKem Technology Co., Ltd.
Phase 2CCC
Ivonescimab
Fudan University
Phase 2CCC
Alpelisib
M.D. Anderson Cancer Center
Phase 1CC
Risvutatug Rezetecan
Nader Sanai
Early Phase 1C

Same molecule, other indications

Adebrelimab is also rated in:

Metastatic Colon CancerDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →